EUVIMEDObjevte EUVIMED
Crossref

Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity

Konstantinos Sechidis iD, Cong Zhang, Sophie Sun, Yao Chen, Asher Spector iD, Björn Bornkamp iD

Statistics in Medicine · 2025-12 · 44 (28-30)

DOI: 10.1002/sim.70324 ↗

At a glance

Journal article in Statistics in Medicine, published online on 2025-11-27. Written by Konstantinos Sechidis and 5 co-authors. Institution: Advanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland. Major MEDLINE topics: Precision Medicine. Cited 5 times so far (Crossref); 77 references. Funded by: Two Sigma Graduate Fellowship Fund, Citadel GQS PhD Fellowship, National Science Foundation.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Assessing treatment effect heterogeneity (TEH) in clinical trials is crucial, as it provides insights into the variability of treatment responses among patients, influencing key decisions related to drug development. Furthermore, it can lead to personalized medicine by tailoring treatments to individual patient characteristics. This paper introduces novel methodologies for assessing treatment effects using the individualized treatment effect as a basis. To estimate this effect, we use a doubly robust (DR) learner to infer a pseudo‐outcome that reflects the causal contrast. This pseudo‐outcome is then used to perform three objectives: (1) a global test for heterogeneity, (2) ranking covariates based on their influence on effect modification, and (3) providing estimates of the individualized treatment effect. We compare the DR‐learner with various alternatives and competing methods in a simulation study, and also use it to assess heterogeneity in a pooled analysis of five Phase III trials in psoriatic arthritis (PsA). By integrating these methods with the recently proposed Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors (WATCH) workflow, we provide a robust framework for analyzing TEH, offering insights that enable more informed decision‐making in this challenging area.

Subjects

MeSH terms (MEDLINE)

Precision MedicineHumansComputer SimulationTreatment OutcomeArthritis, PsoriaticClinical Trials, Phase III as TopicModels, StatisticalTreatment Effect Heterogeneity

Author keywords

conditional average treatment effectheterogeneous treatment effectmachine learningmeta‐learnerssubgroup analysis

Authors and institutions

  • Advanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland.
  • China Novartis Institutes for Bio-medical Research CO., Shanghai, China.
  • Advanced Methodology and Data Science, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Department of Statistics, Stanford University, Stanford, California, USA.

ORCID profiles: Konstantinos Sechidis, Asher Spector, Björn Bornkamp

Funding

  • Two Sigma Graduate Fellowship Fund
  • Citadel GQS PhD Fellowship
  • National Science Foundation

Cite

APA

Sechidis, K., Zhang, C., Sun, S., Chen, Y., Spector, A., & Bornkamp, B. (2025). Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity. Statistics in Medicine, 44(28-30). https://doi.org/10.1002/sim.70324

Vancouver

Sechidis K, Zhang C, Sun S, Chen Y, Spector A, Bornkamp B. Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity. Statistics in Medicine. 2025;44(28-30). doi:10.1002/sim.70324

BibTeX
@article{Sechidis2025,
  author = {Sechidis, Konstantinos and Zhang, Cong and Sun, Sophie and Chen, Yao and Spector, Asher and Bornkamp, Björn},
  title = {Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity},
  journal = {Statistics in Medicine},
  year = {2025},
  volume = {44},
  number = {28-30},
  doi = {10.1002/sim.70324}
}
Start for free →